Changes for page Celsion Corporation
Last modified by Asif Farooqui on 2019/10/09 02:47
Change comment:
There is no comment for this version
Summary
-
Page properties (2 modified, 0 added, 0 removed)
Details
- Page properties
-
- Tags
-
... ... @@ -1,1 +1,0 @@ 1 -US:CLSN - Content
-
... ... @@ -2,124 +2,31 @@ 2 2 {{toc/}} 3 3 {{/box}} 4 4 5 -= Overview=5 += Paragraph 1 = 6 6 7 - Celsion (CLSN) is a fully-integrated developmentstage oncology drug companyfocusedn advancing a portfolioofinnovativecancer treatments,including directed chemotherapies,DNA-mediatedimmunotherapy andRNA basedtherapies. The company's lead productcandidateis ThermoDox®, aproprietaryheat-activated liposomal encapsulation ofdoxorubicin,currentlyin a Phase III clinical trial forthetreatmentof primarylivercancer(the OPTIMA Study)andaPhase II clinicaltrialfor thetreatmentof recurrent chest wall breast cancer (the DIGNITY Study).Secondintspipelineis GEN-1,aDNA-mediatedimmunotherapyfor thelocalizedtreatment of ovarian and braincancers. Celsionhas two platformtechnologiesprovidingthebasisfor thefuturedevelopmentofa rangeoftherapeuticsfor difficult-to-treatformsof cancer including:Lysolipid Thermally Sensitive Liposomes, aheat sensitiveliposomal baseddosageformthattargetsdiseasewithknown therapeuticsin thepresence ofmild heatand TheraPlas,anovel nucleicacid-basedtreatment forlocal transfection of therapeutic plasmids. WiththesetechnologiesCelsion is workingto developndcommercializemore efficient,effective andtargetedoncology therapiesthatmaximize efficacy while minimizingside-effectscommontocancertreatments.{{footnote}}https://fintel.io/doc/sec-clsn-celsion-10k-2018-march-27-17968{{/footnote}}7 +Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. 8 8 9 -= ThermoDox®=9 +== Sub-paragraph == 10 10 11 - ThermoDox®isbeing evaluated inaPhaseIIIclinicaltrialforprimarylivercancer, whichthecompanycalltheOPTIMA Study, whichwasinitiatedin2014 anda PhaseIIclinicaltrial for recurrentchest wall breastcancer,theDIGNITY Study.ThermoDox®isaliposomalencapsulationof doxorubicin,an approvedand frequentlyusedncology drugforthetreatmentofawiderangeof cancers.Localizedheat athyperthermiaemperatures(greaterthan 40° Celsius)releasestheencapsulateddoxorubicinfrom the liposomeenablinghighconcentrationsofdoxorubicinto bedeposited preferentiallyinandaroundthegeted tumor.11 +Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. 12 12 13 - TheOPTIMAStudy. The OPTIMA Study represents an evaluation of ThermoDox® in combination with a first line therapy, radio frequencyablation (RFA), for newly diagnosed, intermediate stage HCCpatients. HCC incidence globally is approximately 850,000 new cases per year and is thethird largest cancer indication globally. Approximately 30% of newly diagnosed patients can be addressed with RFA alone.13 +== Sub-paragraph == 14 14 15 - On February 24, 2014, thecompanyannounced thatthe United StatesFoodandDrug Administration(the“FDA”),afteritscustomary 30-dayreviewperiod, providedclearancefortheOPTIMAStudy,whichisapivotal,double-blind,placebo-controlledPhaseIIItrialofThermoDox®,incombinationwithstandardizedRFA, for the treatmentof primarylivercancer. Thetrialdesign oftheOPTIMA Studyisbasedon thecomprehensiveanalysis ofdatafrom anearlier clinicaltrialcalledtheHEAT Study,whichis describedbelow. The OPTIMA Studyissupportedbyahypothesisdeveloped from an overallsurvivalanalysisofalarge subgroup of patients from the HEAT Study.15 +Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. 16 16 17 - Thecompany initiated the OPTIMAStudy in the first half of 2014. The OPTIMA Study was designed with extensive input from globally recognized hepatocellular carcinoma (“HCC”) researchers and expert clinicians and after receiving formal written consultation from the FDA. The OPTIMA Study is expected to enroll up to 550 patients globallyat upto 70 sites in the United States, Canada, Europe Union, Chinaand other countries in the Asia-Pacific region, and will evaluate ThermoDox® in combination with standardized RFA, which will require a minimum of 45 minutes across all investigators and clinical sites for treating lesions three to seven centimeters, versus standardized RFA alone. Theprimary endpoint for thisclinical trial is overall survival (“OS”), and the secondary endpoints are progression free survival and safety. The statistical plan calls for two interim efficacy analyses by an independent Data Monitoring Committee (DMC).17 +=== Sub-sub paragraph === 18 18 19 - On December16,2015,thecompany announcedthatthecompany had receivedtheclinicaltrialapplicationapprovalfromtheChina Foodand DrugAdministration(the“CFDA”)toconducttheOPTIMA StudyinChina.ThisclinicaltrialapplicationapprovalwillallowCelsion to enroll patientsatupto20 clinicalsitesin China. On April26,2016, the companyannounced thatthe firstpatientinChina hadbeen enrolled in theOPTIMA Study.ResultsfromtheOPTIMAStudy,ifsuccessful,willprovidehebasisforaglobalregistrationfilingandmarketingapproval.19 +Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. 20 20 21 -On August 7, 2017, the Company announced that the independent Data Monitoring Committee (DMC) for the Company's OPTIMA Study completed a regularly scheduled review of the first 50% of patients enrolled in the trial and has unanimously recommended that the OPTIMA Study continue according to protocol to its final data readout. The DMC reviewed study data at regular intervals, with the primary responsibilities of ensuring the safety of all patients enrolled in the study, the quality of the data collected, and the continued scientific validity of the study design. As part of its review of the first 275 patients, the DMC monitored a quality matrix relating to the total clinical data set, confirming the timely collection of data, that all data are current as well as other data collection and quality criteria. 22 22 23 - TheCompany hosted an Investigators Meeting with physicians in South East Asia and key opinion leaders on July 22-23, 2017 in Bangkok, Thailand. A second Investigators Meeting is being planned for October 2017 withphysiciansin China. The Company has initiated approximately 70 clinical sites in 14 countries with plans to activate up to 8 additional clinical trial sites in China or Vietnam by the end of2017.In addition, the Company announced that patient enrollment in the 550 patient Phase III global study has reached over 60%. Based on current enrollment rates, the Company expects to complete enrollment of the study by mid-2018.22 += Paragraph 2 = 24 24 25 - Post-hoc data analysis from theCompany’searlier Phase III HEAT Study suggest that ThermoDox®maysubstantiallyimproveOS,whencomparedto thecontrolgroup,inpatientsftheirlesionsundergoa 45 minute RFA procedurestandardized fora lesiongreater than 3cmindiameter.Datafrom nine OS sweeps havebeen conductedsincehetopline progressionfree survival(“PFS”) datafromtheHEAT Study wereannounced inJanuary 2013,with each datasetdemonstratingsubstantialimprovementin clinicalbenefitoverthe controlgroup withstatisticalsignificance.On August 15, 2016, theCompanyannouncedupdatedresults fromitsfinal retrospectiveOS analysis of the data from the HEAT Study. Theseresultsdemonstratedthatina large, well bounded, subgroup of patientswith a singlelesion (n=285, 41% of the HEAT Studypatients), treatmentwitha combination of ThermoDox® and optimized RFA provided an average 54% risk improvementin OScompared to optimizedRFA alone.TheHazard Ratio (“HR”)atthis analysis is 0.65 (95% CI 0.45 - 0.94) witha p-value of 0.02. Median OS forthe ThermoDox® group has beenreachedwhich translates into a two year survival benefit overtheoptimizedRFA group(projectedtobegreaterthan80 monthsfortheThermoDox® plus optimizedRFA group compared toessthan60monthsprojectionfor theoptimizedRFA only group).24 +Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. 26 26 27 - Additionalfindings from this most recent analysis specific to the Chinese patient cohort of 223 patients are summarizedbelow:26 +== Sub-paragraph == 28 28 29 -* In the population of 154 patients with a single lesion who received optimized RFA treatment for 45 minutes or more showed a 53% risk improvement in OS (HR = 0.66) when treated with ThermoDox® plus optimized RFA. 30 -* These data continue to support and further strengthen ThermoDox®’s potential to significantly improve OS compared to an RFA control in patients with lesions that undergo optimized RFA treatment for 45 minutes or more. The clinical benefit seen in the intent-to-treat Chinese patient cohort further confirms the importance of RFA heating time as 72% of patients in this large patient cohort in China received an optimized RFA treatment. 28 +Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. 31 31 32 - Whilethis information should be viewed with caution since it is based on a retrospective analysis of a subgroup, the company also conducted additional analyses that further strengthen the evidence for the HEATStudy sub-group. The company commissioned an independent computational model at the University of South Carolina Medical School. The results indicate that longerRFA heating times correlate with significant increases in doxorubicin concentration around the RFA treated tissue. In addition, the company conducted a prospective preclinical study in 22 pigs using two different manufacturers of RFA andhumanequivalent doses of ThermoDox® that clearly support the relationship between increased heating duration and doxorubicin concentrations.30 +== Sub-paragraph == 33 33 34 -On November 29, 2016, the Company announced the results of an independent analysis conducted by the National Institutes of Health (the “NIH”) from the HEAT Study which reaffirmed the correlation between increased RFA burn time per tumor volume and improvements in overall survival. The NIH analysis, which sought to evaluate the correlation between RFA burn time per tumor volume (min/ml) and clinical outcome, concluded that increased burn time per tumor volume significantly improved overall survival in patients treated with RFA plus ThermoDox® compared to patients treated with RFA alone. For all patients with single lesions treated with RFA plus ThermoDox®: 35 - 36 -* One unit increase in RFA duration per tumor volume improved overall survival by 20% (p=0.017; n=227); 37 -* More significant differences in subgroup of patients with RFA burn times per tumor volume greater than 2.5 minutes per ml; 38 -* Cox multiple covariate analysis showed overall survival to be significant (p=0.038; Hazard Ratio = 0.85); and 39 -* Burn time per tumor volume did not have a significant effect on overall survival in single lesion patients treated with RFA only. 40 - 41 -The HEAT Study. On January 31, 2013, the Company announced that the HEAT Study, ThermoDox® in combination with RFA, did not meet the primary endpoint, PFS, of a Phase III clinical trial enrolling 701 patients with primary liver cancer. This determination was made after conferring with the HEAT Study independent DMC, that the HEAT Study did not meet the goal of demonstrating a clinically meaningful improvement in progression free survival. In the trial, ThermoDox® was well-tolerated with no unexpected serious adverse events. Following the announcement of the HEAT Study results, the company continued to follow patients for OS, the secondary endpoint of the HEAT Study. Celsion has conducted a comprehensive analysis of the data from the HEAT Study to assess the future strategic value and development strategy for ThermoDox®. 42 - 43 -The DIGNITY Study. On December 14, 2015, the company announced final data from its ongoing DIGNITY study, which is an open-label, dose-escalating Phase II trial of ThermoDox® in patients with recurrent chest wall (“RCW”) breast cancer. The DIGNITY Study was designed to establish a safe therapeutic dose in Phase I, and to demonstrate local control in Phase II, including complete and partial responses, and stable disease as its primary endpoint. The DIGNITY Study was also designed to evaluate kinetics in ThermoDox® produced from more than one manufacturing site. Of the 29 patients enrolled and treated, 21 patients were eligible for evaluation of efficacy. Approximately 62% of evaluable patients experienced a local response, including six complete responses and seven partial responses. 44 - 45 -The Euro-DIGNITY Study. The company anticipate that a Phase II study of RadioTherapy, HyperThermia and ThermoDox® to treat patients with local-regional recurrent chest wall breast cancer will be initiated by five to six clinical sites located in Italy, Israel, Poland and the Czech Republic (the “Euro-DIGNITY Study”). The Euro-DIGNITY Study is expected to commence in the second half of 2017 and should enroll up to 70 patients affected by recurrent breast adenocarcinoma on the chest wall with/without nodes over a period of two years. 46 - 47 -The primary objectives of the Euro-DIGNITY Study will be (i) to evaluate efficacy in patients after 3 cycles of ThermoDox® plus Hyperthermia measuring tumor diameter as a response to therapy and (ii) to evaluate loco-regional breast tumor control in patients who undergo ThermoDox®/hyperthermia/radiotherapy as measured by target lesion clinical response rate combining a RECIST criteria with digital photography to gauge response. 48 - 49 -Secondary objectives of the Euro-DIGNITY Study will be (i) to evaluate the safety of the combination of ThermoDox/Hyperthermia/Radiotherapy among patients with local-regional recurrence (“LRR”) breast cancer, (ii) to evaluate the duration of local control complete response, partial response and stable disease following treatment with ThermoDox/Hyperthermia/Radiotherapy up to 24 months among patients with LRR breast cancer and (iii) to assess Patient Reported Quality of Life using the FACT-B and Brief Pain Inventory following treatment with ThermoDox/Hyperthermia/Radiotherapy among patients with LRR breast cancer. 50 - 51 -= Acquisition of EGEN Assets = 52 - 53 -On June 20, 2014, the company completed the acquisition of substantially all of the assets of Egen, Inc., an Alabama corporation, which has changed its company name to EGWU, Inc. after the closing of the acquisition (“EGEN”), pursuant to an asset purchase agreement dated as of June 6, 2014, by and between EGEN and Celsion (the “Asset Purchase Agreement”). The company acquired all of EGEN’s right, title and interest in and to substantially all of the assets of EGEN, including cash and cash equivalents, patents, trademarks and other intellectual property rights, clinical data, certain contracts, licenses and permits, equipment, furniture, office equipment, furnishings, supplies and other tangible personal property. In addition, CLSN Laboratories assumed certain specified liabilities of EGEN, including the liabilities arising out of the acquired contracts and other assets relating to periods after the closing date. 54 - 55 -The total purchase price for the asset acquisition is up to $44.4 million, including potential future earnout payments of up to $30.4 million contingent upon achievement of certain earnout milestones set forth in the Asset Purchase Agreement. At the closing, the company paid approximately $3.0 million in cash after the expense adjustment and issued 193,728 shares of its common stock to EGEN. The shares of common stock were issued in a private transaction exempt from registration under the Securities Act, pursuant to Section 4(2) thereof. In addition, the Company held back 47,862 shares of common stock issuable to EGEN pending satisfactory resolution of any post-closing adjustments of expenses and EGEN’s indemnification obligations under the EGEN Purchase Agreement (Holdback Shares). These shares were issued on June 16, 2017. 56 - 57 -The earnout payments of up to $30.4 million will become payable, in cash, shares of its common stock or a combination thereof, at its option upon achievement of three major milestone events as follows: 58 - 59 -* $12.4 million will become payable upon achieving certain specified development milestones relating to an ovarian cancer study of GEN-1 (formerly known as EGEN-001) to be conducted by it or its subsidiary; 60 -* $12.0 million will become payable upon achieving certain specified development milestones relating to a GEN-1 glioblastoma multiforme brain cancer study to be conducted by it or its subsidiary; and 61 -* up to $6.0 million will become payable upon achieving certain specified milestones relating to the TheraSilence technology acquired from EGEN in the acquisition. 62 - 63 -The company's obligations to make the earnout payments will terminate on the seventh anniversary of the closing date. In the acquisition, the company purchased GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers, and two platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas and TheraSilence. 64 - 65 -~*~*GEN-1 ~*~* 66 - 67 -GEN-1 is a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers by intraperitoneally administering an Interleukin-12 (“IL-12”) plasmid formulated with its proprietary TheraPlas delivery system. In this DNA-based approach, the immunotherapy is combined with a standard chemotherapy drug, which can potentially achieve better clinical outcomes than with chemotherapy alone. The company believe that increases in IL-12 concentrations at tumor sites for several days after a single administration could create a potent immune environment against tumor activity and that a direct killing of the tumor with concomitant use of cytotoxic chemotherapy could result in a more robust and durable antitumor response than chemotherapy alone. The company believe the rationale for local therapy with GEN-1 are based on the following: 68 - 69 -* Loco-regional production of the potent cytokine IL-12 avoids toxicities and poor pharmacokinetics associated with systemic delivery of recombinant IL-12 70 -* Persistent local delivery of IL-12 lasts up to one week and dosing can be repeated 71 -* Ideal for long-term maintenance therapy 72 - 73 -GEN-1 OVATION Study. In February 2015, the company announced that the FDA accepted, without objection, the Phase I dose-escalation clinical trial of GEN-1 in combination with the standard of care in neo-adjuvant ovarian cancer (the “OVATION Study”). On September 30, 2015, the company announced enrollment of the first patient in the OVATION Study. The OVATION Study will seek to identify a safe, tolerable and potentially therapeutically active dose of GEN-1 by recruiting and maximizing an immune response and is designed to enroll three to six patients per dose level and will evaluate safety and efficacy and attempt to define an optimal dose for a follow-on Phase I/II study combining GEN-1 with Avastin® and Doxil®. In addition, the OVATION Study establishes a unique opportunity to assess how cytokine-based compounds such as GEN-1, directly affect ovarian cancer cells and the tumor microenvironment in newly diagnosed patients. The study is designed to characterize the nature of the immune response triggered by GEN-1 at various levels of the patients’ immune system, including: 74 - 75 -* infiltration of cancer fighting T-cell lymphocytes into primary tumor and tumor microenvironment including peritoneal cavity, which is the primary site of metastasis of ovarian cancer; 76 -* changes in local and systemic levels of immuno-stimulatory and immunosuppressive cytokines associated with tumor suppression and growth, respectively; and 77 -* expression profile of a comprehensive panel of immune related genes in pre-treatment and GEN-1-treated tumor tissue. 78 - 79 -Celsion has initiated the OVATION Study at four clinical sites at the University of Alabama at Birmingham, Oklahoma University Medical Center, Washington University in St. Louis and the Medical College of Wisconsin During 2016 and 2017, the company announced data from the first fourteen patients who completed treatment in the OVATION Study. The results are summarized below: 80 - 81 -* Of the fourteen patients treated to date in the entire study, two (2) patients demonstrated a complete response, ten (10) patients demonstrated a partial response and two (2) patients demonstrated stable disease, as measured by RECIST criteria. This translates to a 100% disease control rate (“DCR”) and an 86% objective response rate (“ORR”). Of the five patients treated in the highest dose cohort, there was a 100% objective response rate with one (1) complete response and four (4) partial responses. 82 -* Fourteen patients had successful resections of their tumors, with nine (9) patients (64%) having an R0 resection, which indicates a microscopically margin-negative resection in which no gross or microscopic tumor remains in the tumor bed. Of the five patients treated at the highest dose cohort, all five patients (100%) experienced a R0 surgical resection. 83 -* One patient demonstrated a pathological complete response (pCR). pCRs are typically seen in less than 7% of patients receiving neoadjuvant chemotherapy followed by surgical resection, and have been associated with a median OS of 72 months, which is more than three years longer than those who do not experience a pCR. 84 -* All patients experienced a clinically significant decrease in their CA-125 protein levels as of their most recent study visit. CA-125 is used to monitor certain cancers during and after treatment. CA-125 is present in greater concentrations in ovarian cancer cells than in other cells. 85 - 86 -Celsion also reported supportive translational research data from the first two patient cohorts who have completed treatment in the OVATION Study. Celsion believes that this translational data demonstrates that GEN-1 is potentially producing beneficial cytokines and potentially impacting T-cells in the tumor. 87 - 88 -Top Line Translational Data from First Two Cohorts 89 - 90 -Celsion also reported initial translational data from the first two cohorts of patients. Tumor and blood samples collected before the start of the neoadjuvant chemotherapy (“NACT”) and after the completion of GEN-1 treatment at debulking surgery are being analyzed for immune cell populations. Top line data demonstrates intriguing immunological changes in the tumor that are consistent with the activation of the immune system. Specifically: 91 - 92 -* In tumor tissue, there was an increase in cytotoxic CD8+ T-cell density in three out of four evaluable patients at debulking surgery. There was a decrease in immunosuppressive FoxP3+ T-cells in two out of those 4 patients. The ratio of CD8+/FoxP3+ cells was increased in all four evaluable patients. High tumor infiltrating CD8+ T-cell density, low FoxP3+ T-cell density or high CD8+/FoxP3+ ratio demonstrate a potential shift in tumor environment to favoring immune stimulation following NACT + GEN-1 therapy. For the remaining two patients the post-treatment tumor tissue was not available. In one of those two patients there was complete pathological response hence no tumor tissue was present to provide a post-treatment comparison. In the other patient the debulking surgery was not performed due to disease related complications. 93 -* In plasma samples, there was no significant change in T-cell density following the treatment. The density of myeloid derived suppressor cells that are associated with immunosuppression in ovarian cancer were either decreased or did not increase in post-treatment samples. 94 - 95 -GEN-1 Plus Doxil® and Avastin® Trial. On April 29, 2015, the company announced the expansion of its ovarian cancer development program to include a Phase I dose escalating trial to evaluate GEN-1 in combination with Avastin® and Doxil® in platinum-resistant ovarian cancer patients. This new combination study in platinum-resistant ovarian cancer is supported by three preclinical studies indicating that the combination of GEN-1 with Avastin® may result in significant clinical benefit with a favorable safety profile. Specifically: 96 - 97 -* In two preclinical studies using an animal model of disseminated ovarian cancer, GEN-1 in combination with Avastin® led to a significant reduction in tumor burden and disease progression. The effectiveness of the combined treatment was seen when GEN-1 was combined with various dose levels of Avastin® (low-medium-high). Additionally, it was shown that GEN-1 treatment alone resulted in anti-tumor activity that was as good as or better than Avastin® treatment alone. 98 -* The preclinical studies indicated that no obvious overt toxicities were associated with the combined treatments of GEN-1 and Avastin®. The preclinical data are also consistent with the mechanism of action for GEN-1, which exhibits certain anti-angiogenic properties and suggests that combining GEN-1 with lower doses of Avastin® may enhance efficacy and help reduce the known toxicities associated with this anti-VEGF drug. 99 -* The distinct biological activities of GEN-1 (immune stimulation) and Avastin® (inhibition of tumor blood vessel formation) also suggest scientific rationale for this combination approach. Additionally, the anti-angiogenic activity of GEN-1 mediated through up regulation of the interferon gamma (“IFN-g”) pathway may help to explain the synergy between GEN-1 and Avastin® and potentially addresses the VEGF escape mechanisms associated with resistance to Avastin® therapy. 100 - 101 -TheraPlas Technology Platform. TheraPlas is a technology platform for the delivery of DNA and messenger RNA (“mRNA”) therapeutics via synthetic non-viral carriers and is capable of providing cell transfection for double-stranded DNA plasmids and large therapeutic RNA segments such as mRNA. There are two components of the TheraPlas™ system, a plasmid DNA or mRNA payload encoding a therapeutic protein and a delivery system. The delivery system is designed to protect the DNA/RNA from degradation and promote trafficking into cells and through intracellular compartments. The company designed the delivery system of TheraPlas by chemically modifying the low molecular weight polymer to improve its gene transfer activity without increasing toxicity. The company believe TheraPlas is a viable alternative to current approaches to gene delivery due to several distinguishing characteristics, including enhanced molecular versatility that allows for complex modifications to improve activity and safety. 102 - 103 -Technology Development and Licensing Agreements. The company's current efforts and resources are applied on the development and commercialization of cancer drugs including tumor-targeting chemotherapy treatments using focused heat energy in combination with heat-activated drug delivery systems, immunotherapies and RNA-based therapies. 104 - 105 -On August 8, 2016, the company signed a Technology Transfer, Manufacturing and Commercial Supply Agreement (the “GEN-1 Agreement”) with Zhejiang Hisun Pharmaceutical Co. Ltd. (Hisun) to pursue an expanded partnership for the technology transfer relating to the clinical and commercial manufacture and supply of GEN-1, Celsion’s proprietary gene mediated, IL-12 immunotherapy, for the greater China territory, with the option to expand into other countries in the rest of the world after all necessary regulatory approvals are obtained. The GEN-1 Agreement will help to support supply for both ongoing and planned clinical studies in the United States, and for potential future studies of GEN-1 in China. GEN-1 is currently being evaluated by Celsion in first line ovarian cancer patients. 106 - 107 -In June 2012, Celsion and Hisun signed a long-term commercial supply agreement for the production of ThermoDox®. Hisun is one the largest manufacturers of chemotherapy agents globally, including doxorubicin. In July 2013, the ThermoDox® collaboration was expanded to focus on next generation liposomal formulation development with the goal of creating safer, more efficacious versions of marketed cancer chemotherapeutics. During 2015, Hisun successfully completed the manufacture of three registration batches for ThermoDox® and has obtained regulatory approvals to supply ThermoDox® to participating clinical trial sites in all of the countries of South East Asia, Europe and North America, as well as to the European Union countries allowing for early access to ThermoDox®. The future manufacturing of clinical and commercial supplies by Hisun will result in a cost structure allowing Celsion to profitably access all global markets, including third world countries, and help accelerate the Company’s product development program in China for ThermoDox® in primary liver cancer and other approved indications. 108 - 109 -= Business Plan and Going Concern = 110 - 111 -As a clinical stage biopharmaceutical company, its business and its ability to execute its strategy to achieve its corporate goals are subject to numerous risks and uncertainties. 112 - 113 -Celsion has not generated and do not expect to generate any revenue from product sales in the next several years, if at all. An element of its business strategy has been to pursue, as resources permit, the research and development of a range of product candidates for a variety of indications. The company may also evaluate licensing cancer products from third parties for cancer treatments to expand its current product pipeline. This is intended to allow it to diversify the risks associated with its research and development expenditures. To the extent Celsion is unable to maintain a broad range of product candidates, its dependence on the success of one or a few product candidates would increase and results such as those announced in relation to the HEAT study on January 31, 2013 will have a more significant impact on its financial prospects, financial condition and market value. The company may also consider and evaluate strategic alternatives, including investment in, or acquisition of, complementary businesses, technologies or products. As demonstrated by the HEAT Study results, drug research and development is an inherently uncertain process and there is a high risk of failure at every stage prior to approval. The timing and the outcome of clinical results are extremely difficult to predict. The success or failure of any preclinical development and clinical trial can have a disproportionately positive or negative impact on its results of operations, financial condition, prospects and market value. 114 - 115 -The company's current business strategy includes the possibility of entering into collaborative arrangements with third parties to complete the development and commercialization of its product candidates. In the event that third parties take over the clinical trial process for one or more of its product candidates, the estimated completion date would largely be under the control of that third party rather than it. The company cannot forecast with any degree of certainty which proprietary products or indications, if any, will be subject to future collaborative arrangements, in whole or in part, and how such arrangements would affect its development plan or capital requirements. The company may also apply for subsidies, grants or government or agency-sponsored studies that could reduce its development costs. 116 - 117 -As of June 30, 2017, Celsion has $3.6 million in cash and cash equivalents. In July 2017, the Company completed a $5 million registered direct equity offering of shares of common stock, or pre-funded warrants in lieu thereof, and a concurrent private placement of warrants to purchase common stock with several institutional healthcare investors. Given its development plans, the company anticipate cash resources will be sufficient to fund its operations through 2017 and the Company has no committed sources of additional capital. The Company has a Controlled Equity Offering SM Sales Agreement (the “ATM Agreement”) with Cantor Fitzgerald & Co. As a result of the risks and uncertainties discussed in its 2016 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, among others, Celsion is unable to estimate the duration and completion costs of its research and development projects or when, if ever, and to what extent the company will receive cash inflows from the commercialization and sale of a product. The company's inability to complete any of its research and development activities, preclinical studies or clinical trials in a timely manner or its failure to enter into collaborative agreements when appropriate could significantly increase its capital requirements and could adversely impact its liquidity. While its estimated future capital requirements are uncertain and could increase or decrease as a result of many factors, including the extent to which the company choose to advance its research, development activities, preclinical studies and clinical trials, or if Celsion is in a position to pursue manufacturing or commercialization activities, the company will need significant additional capital to develop its product candidates through development and clinical trials, obtain regulatory approvals and manufacture and commercialize approved products, if any. The company do not know whether the company will be able to access additional capital when needed or on terms favorable to it or its stockholders. The company's inability to raise additional capital, or to do so on terms reasonably acceptable to it, would jeopardize the future success of its business. Based on the above, management has determined there is substantial doubt regarding its ability to continue as a going concern. As a result, its independent registered accounting firm has expressed substantial doubt about its ability to continue as a going concern in their report dated March 24, 2017 included in its 2016 Annual Report on Form 10-K. 118 - 119 -= Reverse Stock Split = 120 - 121 -On May 26, 2017, the Company effected a reverse stock split of its common stock at an exchange ratio of 14-to-1 (the “Reverse Stock Split”) and set the number of authorized shares of common stock outstanding immediately after the split at 112.5 million shares. As a result of the Reverse Stock Split, every fourteen shares of common stock outstanding immediately prior to the effectiveness of the Reverse Stock Split were combined and converted into one share of common stock immediately thereafter without any change in the per share par value. The Company’s common stock started to trade on the post-split basis at the commencement of trading on May 30, 2017 under a new CUSIP number 15117N503 with the same ticker symbol, CLSN. Unless otherwise expressly stated, the share and per share data in this section and elsewhere in this Quarterly Report on Form 10-Q have been adjusted to reflect the Reverse Stock Split. 122 - 123 -= References = 124 - 125 -{{putFootnotes/}} 32 +Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.